MedTrace Logo

Genotyping Infarct Patients to Adjust and Normalize Thienopyridine Treatment

NCT01134380 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2014-10-08

No results posted yet for this study

Summary

The objective of GIANT Study is to evaluate the clinical impact of genetic resistance to thienopyridine profile determination (CYP2C19 gene) and the clinical impact of compliance to an adjusted thienopyridine treatment on STEMI patients treated by primary PCI within the 24 hours following the first chest pain.

Conditions

  • Coronary Artery Disease
  • Acute Coronary Syndrome
  • Genetic Resistance to Clopidogrel
  • Compliance to Thienopyridine Treatment

Sponsors & Collaborators

  • European Cardiovascular Research Center

    collaborator NETWORK

  • Allies in Cardiovascular Trials Initiatives and Organized

    collaborator OTHER

  • Biotronik France

    lead INDUSTRY

Principal Investigators

  • Bernard Chevalier · Hopital Privé Jacques Cartier

  • Gilles Montalescot · Assistance Publique - Hôpitaux de Paris

  • Loïc Belle · Centre Hospitalier de la région Annecienne

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01134380 on ClinicalTrials.gov